Brady Gleason

Brady P. Gleason is a Director in Sterne Kessler's Trial & Appellate Practice Group, where he focuses on complex intellectual property disputes. His practice areas encompass pharmaceutical, biotechnology, and mechanical and chemical engineering fields. His experience includes litigation in federal district courts, appeals before the U.S. Court of Appeals for the Federal Circuit, and Section 337 investigations at the U.S. International Trade Commission.

While the tracked cases show Mr. Gleason representing Tempus AI Inc. as plaintiff, his broader experience at Sterne Kessler demonstrates a versatile approach, litigating on behalf of both plaintiffs and defendants. He represented a plaintiff in Twinstrand Biosciences v. Guardant Health, securing a willful infringement finding and an $83.4 million damages award after a jury trial. Conversely, he also obtained a non-infringement finding for a defendant after a bench trial in Corcept Therapeutics v. Teva Pharmaceuticals Inc..

In his tracked appearances, Mr. Gleason acted as counsel for Tempus AI Inc. in Tempus AI Inc. v. Guardant Health Inc., a case involving oncology diagnostic technologies, including computational methods for analyzing tumor-derived genomic data for liquid biopsy and tissue-based cancer testing platforms. This litigation was transferred from the Southern District of California to the Northern District of California. He also has experience with inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB).

Mr. Gleason earned his J.D., magna cum laude, with a concentration in intellectual property from The Catholic University of America Columbus School of Law, and holds a B.S. in biological sciences from Clemson University. He is admitted to practice in the District of Columbia and Virginia, as well as before the U.S. Court of Appeals for the Federal Circuit and the U.S. District Court for the District of Columbia.